Analysis of influence factors in frequent acute exacerbations of chronic obstructive pulmonary disease
SUN Zeli DING Guozheng
Department of Respiratory Medicine, Anqing Hospital Affiliated to Anhui Medical University Anqing Municipal Hospital, Anhui Province, Anqing 246000, China
Abstract：Objective To analyze influence factors in frequent acute exacerbations of chronic obstructive pulmonary disease (COPD). Methods The clinical data of 151 patients admitted to Department of Respiratory Medicine of Anqing Municipal Hospital, Anhui Province due to acute exacerbations of COPD from October 2018 to October 2019 were retrospectively studied. They were divided into two groups according to the frequency of acute exacerbations in the previous year (October 2017 to September 2018) (≥2 times was frequent group [78 cases], and ＜2 times was infrequent group [73 cases] ). The related indicators of two groups (neutrophil count [N], lymphocyte count [L], neutrophil / lymphocyte ratio [NLR], platelet count [PLT], platelet / lymphocyte ratio [PLR], uric acid [UA], creatinine [Cr], uric acid / creatinine ratio [UA/Cr], CO2 partial pressure of arterial blood [PaCO2], duration, hospitalization days) were compared. Spearman correlation coefficient was used to analyze the relationship between those indicators and frequent acute exacerbations of COPD. Receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of NLR, PLR, UA, UA/Cr, PaCO2 and L in frequent acute exacerbations of COPD. Results NLR, PLR, UA, UA/Cr and PaCO2 in frequent group were higher than those in infrequent group, L was lower than that in infrequent group, disease duration and hospitalization days were longer than those in infrequent group, the differences were statistically significant (all P ＜ 0.05). The frequency of acute exacerbation in the previous year was positively correlated with NLR, PLR, UA, UA/Cr and PaCO2 (rs ＞ 0, P ＜ 0.05), and negatively correlated with L (rs ＜ 0, P ＜ 0.05). ROC curve analysis showed that the area under the curve of these indicators was ＞0.5, and the differences were statistically significant (all P ＜ 0.05). Conclusion NLR, PLR, UA, UA/Cr, PaCO2, and L values may be used as biomarkers to predict frequent acute exacerbations of COPD.
[1] 陈亚红.2020年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J].中国医学前沿杂志：电子版，2019， 11（12）：32-50.
[2] Quaderi SA，Hurst JR. The unmet global burden of COPD [J]. Glob Health Epidemiol Genom，2018，3：e4.
[3] Soler-Catalu?觡a JJ，Rodriguez-Roisin R. Frequent chronic obstructive pulmonary disease exacerbators：how much real，how much fictitious？ [J]. COPD，2010，7（4）：276-284.
[4] Wedzicha JA，Singh R，Mackay AJ. Acute COPD Exacerbations [J]. Clin Chest Med，2014，35（1）：157-163.
[5] 蔡柏蔷，陈荣昌.慢性阻塞性肺疾病急性加重（AECOPD）诊治中国专家共识（2017年更新版）[J].国际呼吸杂志，2017，37（14）：1041-1057.
[6] Arora S，Madan K，Mohan A，et al. Serum inflammatory markers and nutritional status in patients with stable chronic obstructive pulmonary disease [J]. Lung India，2019，36（5）：393-398.
[7] Xiong W，Xu M，Zhao Y，et al. Can we predict the prognosis of COPD with a routine blood test？[J]. Int J Chron Obstruct Pulmon Dis，2017，12：615-625.
[8] Lee H，Um SJ，Kim YS，et al. Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease [J]. PLoS One，2016，11（6）：e0156511.
[9] 王媛，叶蕊，朱丽华，等.NLR、RDW、6MWD在稳定期慢性阻塞性肺疾病频繁急性加重表型中的临床价值[J].国际呼吸杂志，2020，40（11）：834-837.
[10] 张颖，林英翔.慢性阻塞性肺疾病急性加重住院患者一年及长期死亡风险因素分析[J].中华结核和呼吸杂志，2019，42（12）：895-900.
[11] 陈杰，孙耕耘.慢性阻塞性肺疾病频繁加重的多因素分析[J].中华疾病控制杂志，2019，23（3）：341-344.
[12] 田荣华，吴震，王海波，等.慢性阻塞性肺疾病患者外周血中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值的表达及意义[J].中国综合临床，2017，33（5）：433-436.
[13] 王丽芳，韩寒，施斌.红细胞分布宽度联合中性粒细胞/淋巴细胞比值对慢性阻塞性肺疾病急性加重期患者预后的评估价值[J].中国医药导报，2020，17（35）：34-37.
[14] Papadopoulos A，Bartziokas K，Haniotou A，et al. Serum uric acid and uric acid /creatinine ratio in exacerbations of COPD [J]. Eur Respir J，2014，43（1）：43-53.
[15] 沈剑，钱翠，高航，等.慢性阻塞性肺疾病急性加重期患者血尿酸肌酐比与疾病严重程度相关性研究[J].中华肺部疾病杂志：电子版，2013，6（5）：437-439.
[16] Nagihan DK，Sasak G，Ulku AA，et al. Serum Uric Acid Levels and Uric Acid/Creatinine Ratios in Stable Chronic Obstructive Pulmonary Disease（COPD）Patients：Are These Parameters Efficient Predictors of Patients at Risk for Exacerbation and/or Severity of Disease [J]. Med Sci Monit，2016，22：4169-4176.
[17] Abdelhalim HA，Heba HA. Serum uric acid levels and uric acid/creatinine ratios：affordable biomarkers for predicting chronic obstructive pulmonary disease severity and exacerbations [J]. Egyptin Journal of Chest Diseases and Tuberculosis，2018， 67（3）：231-236.
[18] Lada R，Iva H，Sanja PG，et al. Uric acid and uric acid to creatinine ratio in the assessment of chronic obstructive pulmonary disease：Potential biomarkers in multicomponent models comprising IL-1beta [J]. PLoS One，2020，15（6）：e0234363.
[19] Kang DH，Ha SK. Uric Acid Puzzle：Dual Role as Anti-oxidantand Pro-oxidant [J]. Electrolyte Blood Press，2014， 12（1）：1-6.
[20] Bartziokas K，Papaioannou AI，Loukides S，et al. Serum uric acid as a predictor of mortality and future exacerbations of COPD [J]. Eur Respir J，2014，43（1）：43-53.
[21] Macnee W. Oxidants/antioxidants and chronic obstructive pulmonary disease：pathogenesis to therapy [J]. Novartis Found Symp，2001，234：169-188.
[22] Mercuro G，Vitale C，Cerquetani E，et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk [J]. Am J Cardiol，2004，94（7）：932-935.
[23] Sarangi R, Varadhan N, Bahinipati J，et al. Serum Uric Acid in Chronic Obstructive Pulmonary Disease：A Hospital Based Case Control Study [J]. J Clin Diagn Res，2017，11（9）：BC09-BC13.
[24] Aida Y，Shibata Y，Osaka D，et al. The relationship between serum uric acid and spirometric values in participants in a health check：the Takahata study [J]. Int J Med Sci，2011，8（6）：470-478.
[25] 代立志，施炜，丁国正.慢性阻塞性肺疾病急性加重患者严重程度的预测因素评估[J].临床肺科杂志，2020， 25（6）：839-842.
[26] 张霞，侯芳，苏丽，等.多学科合作早期康复干预对老年慢性阻塞性肺疾病急性加重期合并呼吸衰竭患者ICU获得性衰弱的预防效果[J].中国医药导报，2019，16（32）：123-126.
[27] Hiroshi S，Masaharu N，Eiji S，et al. Tissue Hypoxia in Sleep Apnea Syndrome Assessed by Uric Acid and Adenosine [J]. Chest，2002，122（5）：1686-1694.
京公网安备 11010502046598号